NASDAQ:CAPR Capricor Therapeutics (CAPR) Stock Price, News & Analysis $13.03 -0.25 (-1.88%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$12.65 -0.38 (-2.92%) As of 04/25/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Capricor Therapeutics Stock (NASDAQ:CAPR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Capricor Therapeutics alerts:Sign Up Key Stats Today's Range$12.59▼$13.3550-Day Range$8.70▼$15.8052-Week Range$3.52▼$23.40Volume935,939 shsAverage Volume1.50 million shsMarket Capitalization$595.17 millionP/E RatioN/ADividend YieldN/APrice Target$34.50Consensus RatingBuy Company OverviewCapricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders. Read More… Capricor Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks35th Percentile Overall ScoreCAPR MarketRank™: Capricor Therapeutics scored higher than 35% of companies evaluated by MarketBeat, and ranked 749th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCapricor Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCapricor Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Capricor Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Capricor Therapeutics are expected to grow in the coming year, from ($1.21) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Capricor Therapeutics is -12.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Capricor Therapeutics is -12.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCapricor Therapeutics has a P/B Ratio of 17.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Capricor Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.24% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 2.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCapricor Therapeutics does not currently pay a dividend.Dividend GrowthCapricor Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted23.24% of the float of Capricor Therapeutics has been sold short.Short Interest Ratio / Days to CoverCapricor Therapeutics has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Capricor Therapeutics has recently increased by 2.54%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News Sentiment0.74 News SentimentCapricor Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Capricor Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 4 people have searched for CAPR on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows8 people have added Capricor Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Capricor Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.50% of the stock of Capricor Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.68% of the stock of Capricor Therapeutics is held by institutions.Read more about Capricor Therapeutics' insider trading history. Receive CAPR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Capricor Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CAPR Stock News HeadlinesCapricor Therapeutics Inc (CAPR) Q4 2024 Earnings Call Highlights: Navigating Financial ...April 21, 2025 | gurufocus.comCapricor Therapeutics Sees Unusually Large Options Volume (NASDAQ:CAPR)April 18, 2025 | americanbankingnews.comFrom Social Security to Social Prosperity?In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.April 26, 2025 | Paradigm Press (Ad)Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio DayApril 1, 2025 | markets.businessinsider.comCheck Out What Whales Are Doing With CAPRMarch 28, 2025 | benzinga.comCapricor Therapeutics Announces FDA Acceptance of Biologics License Application for Deramiocel in Duchenne Muscular Dystrophy CardiomyopathyMarch 21, 2025 | nasdaq.comIs Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy?March 21, 2025 | msn.comCapricor Therapeutics Full Year 2024 Earnings: Beats ExpectationsMarch 21, 2025 | finance.yahoo.comSee More Headlines CAPR Stock Analysis - Frequently Asked Questions How have CAPR shares performed this year? Capricor Therapeutics' stock was trading at $13.80 on January 1st, 2025. Since then, CAPR shares have decreased by 5.6% and is now trading at $13.03. View the best growth stocks for 2025 here. How were Capricor Therapeutics' earnings last quarter? Capricor Therapeutics Inc (NASDAQ:CAPR) released its earnings results on Wednesday, March, 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating analysts' consensus estimates of ($0.31) by $0.15. The biotechnology company had revenue of $11.13 million for the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative trailing twelve-month return on equity of 112.95% and a negative net margin of 146.86%. Read the conference call transcript. Who are Capricor Therapeutics' major shareholders? Top institutional shareholders of Capricor Therapeutics include Oppenheimer & Co. Inc. (0.28%), HBK Sorce Advisory LLC (0.11%), Rhumbline Advisers (0.11%) and Krilogy Financial LLC (0.05%). Insiders that own company stock include Shinyaku Co Ltd Nippon, David B Musket, Paul Gisbert Auwaerter and Xavier Avat. View institutional ownership trends. How do I buy shares of Capricor Therapeutics? Shares of CAPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Capricor Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Capricor Therapeutics investors own include Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Moderna (MRNA), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings3/19/2025Today4/25/2025Next Earnings (Estimated)5/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CAPR CIK1133869 Webwww.capricor.com Phone310-358-3200Fax415-875-7075EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$34.50 High Stock Price Target$77.00 Low Stock Price Target$15.00 Potential Upside/Downside+165.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,290,000.00 Net Margins-146.86% Pretax Margin-146.86% Return on Equity-112.95% Return on Assets-57.00% Debt Debt-to-Equity RatioN/A Current Ratio4.19 Quick Ratio4.19 Sales & Book Value Annual Sales$22.27 million Price / Sales26.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.73 per share Price / Book17.79Miscellaneous Outstanding Shares45,677,000Free Float40,014,000Market Cap$593.34 million OptionableOptionable Beta4.65 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CAPR) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Capricor Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Capricor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.